Filaminast

Chemical compound
  • None
Legal statusLegal status
  • Development terminated
Identifiers
  • [(E)-1-(3-Cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate
CAS Number
  • 141184-34-1
PubChem CID
  • 9578243
DrugBank
  • DB02660
ChemSpider
  • 7852607
UNII
  • CDD69JC61J
KEGG
  • D04185
Chemical and physical dataFormulaC15H20N2O4Molar mass292.335 g·mol−13D model (JSmol)
  • Interactive image
  • CC(=NOC(=O)N)C1=CC(=C(C=C1)OC)OC2CCCC2

Filaminast (code name WAY-PDA 641)[1] was a drug candidate developed by Wyeth-Ayerst.[2]: Table 2  It is a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts.[3][4]: 668, 678  It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.[4]: 678 

See also

  • Piclamilast
  • Roflumilast

References

  1. ^ "Filaminist entry". Pubchem.
  2. ^ Halpin DM (2008). "ABCD of the phosphodiesterase family: interaction and differential activity in COPD". International Journal of Chronic Obstructive Pulmonary Disease. 3 (4): 543–61. doi:10.2147/COPD.S1761. PMC 2650605. PMID 19281073.
  3. ^ Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology. 155 (3): 288–90. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
  4. ^ a b McKenna JM, Muller GW (5 December 2006). "Medicinal Chemistry of PDE4 Inhibitors. Chapter 33". In Beavo JA, Francis SH, Houslay MD (eds.). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press. ISBN 978-1-4200-2084-7.
  • v
  • t
  • e
Phosphodiesterase inhibitors
PDE1PDE2
PDE3PDE4
PDE5PDE7PDE9PDE10
PDE11
BC11-38
Non-selectiveUnsorted
See also: Receptor/signaling modulators
  • v
  • t
  • e
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products